New drug cocktail targets Hard-to-Treat cancers
NCT ID NCT06520488
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a new drug called HRS-4642 combined with other anti-cancer agents in people with advanced solid tumors that have a KRAS G12D mutation. The trial has two phases: first to find the safest dose, then to see how well the combination works. About 118 adults aged 18-75 with good performance status are being recruited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-4642 combined with SHR-A1921, SHR-A1904, or AG
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that have a specific KRAS G12D mutation.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so the combination may not prove effective or safe. Side effects from the drug combinations are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200127, China
Contact